Product Name : Pirfenidone
Trade Name : Pirfenidone
Available Strength : 200 mg
Packing : 10 Tablets
Pack Insert/Leaflet : Yes
Therapeutic use : Generic Drugs
Production Capacity : 10 million tablet/month
Pirfenidone is used in the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF). IPF is chronic fibrotic and inflammatory lung disease where the lungs tissues become swollen and scarred over time due to synthesis and release of certain chemicals (pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-1-beta ), causing difficulty in breathing.
Pirfenidone is an anti-fibrotic and anti-inflammatory agent and belongs to a class of medications called pyridones. Pirfenidone relieves conditions of idiopathic pulmonary fibrosis by reducing fibroblast growth (cells of the connective tissue which produce collagen and other fibres), reducing production of inflammatory chemicals and preventing accumulation of cell contents (extracellular matrix), thereby relieving swelling and inflammation of the lungs.
indigestion or stomach upset, dry skin, cough, itchy skin, shortness of breath, abdominal pain and discomfort, skin redness or red skin, skin rash, vomiting, aching joints/joint pains, muscle pain, feeling sleepy, headache.Common: infections of the throat or the airways spreading to the lungs and/or sinusitis, tiredness, acid reflux, chest pain and sun burns.Uncommon: feeling weak or feeling low in energy., urge to vomit, heart burn, feeling constipated and passing wind, hot flushes, loss of appetite, diarrhea, feeling weak or feeling low in energy, change is taste, dizziness, bladder infections, Very common: skin reactions after going out in the sun or using sunlamp, weight loss, feeling bloated, difficulty in sleeping
Pirfenidone is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF). FDA approval of two new drugs for idiopathic pulmonary fibrosis (Esbriet and Ofev) offers new hope for patients who live with this deadly, incurable disease. The U.S. Food and Drug Administration has approved Esbriet (pirfenidone), a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
The most widely recognized markets for this item incorporate the accompanying nations. If you don’t mind ask with us if your nation or district isn’t recorded:
ASIA: Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Afghanistan, Israel, Jordan, Pakistan, Russia, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, and so forth..
AFRICA: South Africa, Uganda, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, and so forth.
NORTH & SOUTH AMERICA: Dominican Republic, Argentina, Guatemala, Guyana, Peru, Bolivia, Venezuela, USA, Canada, Panama, Trinidad and Tobago, Costa Rica, Puerto Rico, Brazil, Bahamas, Ecuador, and so forth .
EUROPE: France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Austria, Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, and so forth.
OCEANIA: Fiji, Australia, New Zealand, and so forth.